If you liked this article you might like

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

Celgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact

S&P 500, Dow Barely Beat Records in Little-Changed Session

S&P 500, Dow Barely Beat Records in Little-Changed Session